Organon & Co. (NYSE:OGN) Sets New 1-Year Low – Here’s What Happened

Organon & Co. (NYSE:OGN) reached a new 52-week low during mid-day trading on Tuesday . The stock traded as low as $5.76 and last traded at $6.1050, with a volume of 5920057 shares traded. The stock had previously closed at $6.03.

Analyst Ratings Changes

Several equities research analysts have commented on OGN shares. Barclays boosted their target price on shares of Organon & Co. from $7.50 to $8.00 and gave the stock an “underweight” rating in a research report on Tuesday, February 24th. Wall Street Zen lowered shares of Organon & Co. from a “buy” rating to a “hold” rating in a research report on Saturday, January 31st. Finally, Zacks Research cut shares of Organon & Co. from a “hold” rating to a “strong sell” rating in a report on Thursday, January 29th. One investment analyst has rated the stock with a Strong Buy rating, one has assigned a Hold rating and five have given a Sell rating to the stock. According to data from MarketBeat, Organon & Co. presently has an average rating of “Reduce” and a consensus price target of $8.50.

Organon & Co. Stock Performance

The company has a current ratio of 1.82, a quick ratio of 1.23 and a debt-to-equity ratio of 11.47. The stock’s 50 day moving average price is $7.59 and its two-hundred day moving average price is $8.09. The firm has a market capitalization of $1.59 billion, a PE ratio of 8.58, a PEG ratio of 0.56 and a beta of 0.60.

Organon & Co. (NYSE:OGN) last posted its earnings results on Thursday, February 12th. The company reported $0.63 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.73 by ($0.10). The company had revenue of $1.51 billion during the quarter, compared to analysts’ expectations of $1.52 billion. Organon & Co. had a net margin of 3.01% and a return on equity of 122.01%. Organon & Co.’s quarterly revenue was down 5.3% compared to the same quarter last year. During the same period in the previous year, the company posted $0.90 EPS. On average, equities analysts expect that Organon & Co. will post 3.68 earnings per share for the current year.

Organon & Co. Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Thursday, March 12th. Investors of record on Monday, February 23rd were paid a dividend of $0.02 per share. The ex-dividend date of this dividend was Monday, February 23rd. This represents a $0.08 dividend on an annualized basis and a dividend yield of 1.3%. Organon & Co.’s dividend payout ratio (DPR) is presently 11.27%.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in OGN. Foster Dykema Cabot & Partners LLC purchased a new stake in shares of Organon & Co. during the third quarter worth about $29,000. Farther Finance Advisors LLC grew its stake in Organon & Co. by 87.8% in the 4th quarter. Farther Finance Advisors LLC now owns 4,349 shares of the company’s stock worth $31,000 after acquiring an additional 2,033 shares during the period. Rothschild Investment LLC grew its stake in Organon & Co. by 73.1% in the 3rd quarter. Rothschild Investment LLC now owns 3,899 shares of the company’s stock worth $42,000 after acquiring an additional 1,646 shares during the period. Eurizon Capital SGR S.p.A. acquired a new position in Organon & Co. in the 4th quarter valued at $44,000. Finally, Kestra Advisory Services LLC purchased a new position in shares of Organon & Co. during the 4th quarter worth $47,000. 77.43% of the stock is currently owned by hedge funds and other institutional investors.

About Organon & Co.

Organon & Co is a global healthcare company that was established as an independent, publicly traded entity following its spin-off from Merck & Co in June 2021. Headquartered in Jersey City, New Jersey, Organon focuses on delivering therapeutic solutions across women’s health, biosimilars, and established brands. The company’s creation reflected a strategic effort to concentrate on specialty pharmaceuticals and legacy products with proven patient impact.

In women’s health, Organon provides a broad portfolio of products addressing reproductive and gynecological conditions, including fertility treatments, contraception, and hormone replacement therapies.